Fereshteh Ezzatighadi

Abstract Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients will eventually relapse or become refractory to the treatments. Novel agents are currently in development for the treatment of relapsed/refractory MM, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cell signaling targeted therapies, and strategies targeting the tumor microenvironment. for this purpose the conformational structure of the hexapeptide H3N+-FDDARL-COO-, H3N+-FVDVRLCOO-, H3N+-FSDARL-COO- has been investigated by the PCILO method. The computational results show this tree structure have no functionality group for bind to M protein. Moreover, H3N+-FVDVRL-COO- has assumes the somewhat amphipathic structure.